Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21224168 | 1.00 | RAB9A (0.40) | RAB9AMEN1KMT2ANPC1TSHR | |
| SCHEMBL2856571 | 0.85 | TP53 (0.41) | RAB9AMEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL4858133 | 0.82 | RAB9A (0.36) | RAB9AMEN1KMT2ACCNB2CDK1 | |
| SCHEMBL10018131 | 0.82 | RAB9A (0.43) | RAB9AMEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL6218681 | 0.78 | TP53 (0.39) | RAB9AMEN1KMT2ANPC1TSHR | |
| SCHEMBL3695981 | 0.77 | ESR1 (0.43) | RAB9A | |
| SCHEMBL21140944 | 0.77 | HTR2A (0.46) | RAB9AMEN1KMT2ATSHR | |
| SCHEMBL23288918 | 0.77 | MEN1 (0.36) | RAB9AMEN1KMT2ACCNB2CDK1 | |
| SCHEMBL24216109 | 0.77 | KDM1A (0.53) | RAB9AMEN1KMT2ACCNB2CDK1 | |
| SCHEMBL3711765 | 0.77 | ABCC9 (0.44) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4043466-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | Mirati Therapeutics, Inc. (US) | 2022-11-01 | — | — | US | disclosed |
| EP-4043466-A1 | PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3746446-B1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| CN-114269748-A | Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer | 米拉蒂医疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371435-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | RAB9A 1122/4885MEN1 1695/4885KMT2A 8/4885 |
| US-11485738-B2 | Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors | EZH2, BMI1, SUZ12 | RAB9A 2161/4885MEN1 3197/4885KMT2A 28/4885 |
| US-20250282787-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | RAB9A 2161/4885MEN1 3197/4885KMT2A 28/4885 |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | RAB9A 2161/4885MEN1 3197/4885KMT2A 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.